Adaptive Biotechnologies (ADPT) closed at $29.36 on November 10, 2026, down 3.0% from the previous close, on volume of 1,690,332 shares (30-day average 2,169,033).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Strangle or Risk Reversal | 20-Nov-2622.5 P : 30 C | 2,800 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
TipRanks (Tue, 10-Nov 7:20 AM ET)
Adaptive Biotechnologies: Buy Rating Reiterated as Strong clonoSEQ Growth Supports $34 Price Target
TipRanks (Fri, 6-Nov 9:06 AM ET)
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Adaptive Biotechnologies (ADPT)
TipRanks (Thu, 5-Nov 9:10 AM ET)
Piper Sandler Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
TipRanks (Thu, 5-Nov 7:29 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Thu, 5-Nov 7:25 AM ET)
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
Globe Newswire (Fri, 25-Sep 8:03 AM ET)
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Adaptive Biotechnologies trades on the NASDAQ stock market under the symbol ADPT.
As of November 10, 2026, ADPT stock price declined to $29.36 with 1,690,332 million shares trading.
ADPT has a beta of 0.10, meaning it tends to be less sensitive to market movements. ADPT has a correlation of 0.00 to the broad based SPY ETF.
ADPT has a market cap of $4.69 billion. This is considered a Mid Cap stock.
Last quarter Adaptive Biotechnologies reported $84 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $12 million and missed earnings estimates by -$.03.
In the last 3 years, ADPT traded as high as $30.81 and as low as $2.28.
The top ETF exchange traded funds that ADPT belongs to (by Net Assets): VTI, IWM, ARKG, VB, IWO.
ADPT has outperformed the market in the last year with a price return of +98.5% while the SPY ETF gained +12.9%. ADPT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +17.8% and +11.8%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
ADPT support price is $29.03 and resistance is $31.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADPT shares will trade within this expected range on the day.
